Home / Health / Alzheimer's Trials Lack Diversity: Barriers Remain
Alzheimer's Trials Lack Diversity: Barriers Remain
14 Jul
Summary
- Marginalized communities face exclusion from Alzheimer's research.
- Lack of trust and health equity hinder diverse participation.
- Community co-development is key to inclusive clinical trials.
Barriers to diversity persist in Alzheimer's disease research, affecting participation from Black, Hispanic, Indigenous, Asian, and LGBTQ+ communities. Experts identified a lack of public trust, health equity issues, and logistical hurdles as significant obstacles during a panel at the 2026 Alzheimer's Association International Conference in London. Inclusive representation is deemed essential for ethical and scalable research.
To enhance participation, institutions must dismantle barriers and consider co-developing trials with communities. Tailored educational materials and incentives are vital for specific cultural groups. Moving research into community settings addresses logistical challenges like travel and cost, making participation more accessible for those historically excluded.
Similar diversity challenges impact other research areas, such as HIV/AIDS studies in sub-Saharan Africa and transgender inclusion in US clinical trials. A flexible, transparent, and open dialogue with communities is crucial for generating reliable data that reflects the global population and shapes future Alzheimer's care.
